Lexeo Therapeutics Inc (NASDAQ: LXEO) kicked off on Thursday, up 1.60% from the previous trading day, before settling in for the closing price of $4.38. Over the past 52 weeks, LXEO has traded in a range of $1.45-$19.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -99.98% over the past five years. While this was happening, its average annual earnings per share was recorded 14.56%. With a float of $22.90 million, this company’s outstanding shares have now reached $33.19 million.
Let’s look at the performance matrix of the company that is accounted for 72 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Lexeo Therapeutics Inc (LXEO) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Lexeo Therapeutics Inc is 31.02%, while institutional ownership is 90.35%. The most recent insider transaction that took place on May 16 ’25, was worth 2,979. In this transaction Chief Executive Officer of this company sold 1,074 shares at a rate of $2.77, taking the stock ownership to the 221,173 shares. Before that another transaction happened on May 16 ’25, when Company’s Chief Medical Officer sold 585 for $2.77, making the entire transaction worth $1,623. This insider now owns 67,681 shares in total.
Lexeo Therapeutics Inc (LXEO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 14.56% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.09% during the next five years compared to -99.98% drop over the previous five years of trading.
Lexeo Therapeutics Inc (NASDAQ: LXEO) Trading Performance Indicators
Take a look at Lexeo Therapeutics Inc’s (LXEO) current performance indicators. Last quarter, stock had a quick ratio of 3.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.31, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.02 in one year’s time.
Technical Analysis of Lexeo Therapeutics Inc (LXEO)
Lexeo Therapeutics Inc (NASDAQ: LXEO) saw its 5-day average volume 0.47 million, a negative change from its year-to-date volume of 0.71 million. As of the previous 9 days, the stock’s Stochastic %D was 82.78%.
During the past 100 days, Lexeo Therapeutics Inc’s (LXEO) raw stochastic average was set at 73.17%, which indicates a significant decrease from 94.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.36% in the past 14 days, which was lower than the 159.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.59, while its 200-day Moving Average is $5.45. Nevertheless, the first resistance level for the watch stands at $4.53 in the near term. At $4.60, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.71. If the price goes on to break the first support level at $4.35, it is likely to go to the next support level at $4.24. The third support level lies at $4.17 if the price breaches the second support level.
Lexeo Therapeutics Inc (NASDAQ: LXEO) Key Stats
The company with the Market Capitalisation of 147.73 million has total of 33,197K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -98,330 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -32,660 K.
